Avacta Group Plc/£AVCT
1D1W1MYTD1Y5YMAX
Capital at risk
About Avacta Group Plc
Avacta Group plc is a UK-based clinical-stage biopharmaceutical company focused on precision oncology therapies. Its core development platform, pre|CISION, uses a peptide linker designed to be cleaved by fibroblast activation protein, a protease associated with many solid tumours, with the aim of releasing cytotoxic payloads in the tumour microenvironment while reducing systemic exposure. The clinical pipeline includes faridoxorubicin (AVA6000), a tumour-activated form of doxorubicin, and AVA6103, a pre|CISION peptide drug conjugate incorporating exatecan. The company also owns the Affimer platform, comprising engineered binding proteins that can be used in therapeutic drug conjugates and diagnostic or research applications. Avacta is headquartered at Imperial College’s White City campus in London and has been transitioning to a pure-play oncology therapeutics business through the divestment of its diagnostics operations.
- Ticker
- £AVCT
- Sector
- Health
- Primary listing
- AIM
- Employees
- 81
- Headquarters
- London, United Kingdom
- Website
- avacta.com
Avacta Group Plc Metrics
BasicAdvanced
£365M
-
-£0.10
-0.11
-
Price and volume
Market cap
£365M
Beta
-0.11
52-week high
£0.92
52-week low
£0.48
Average daily volume
1.5M
Financial strength
Current ratio
0.887
Quick ratio
0.838
Long term debt to equity
0.2
Total debt to equity
7.151
Interest coverage (TTM)
-4.18%
Profitability
EBITDA (TTM)
-28.791
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-34,169.91%
Operating margin (TTM)
-26,756.64%
Effective tax rate (TTM)
-0.60%
Management effectiveness
Return on assets (TTM)
-48.65%
Return on equity (TTM)
-616.89%
Valuation
Price to revenue (TTM)
2,758.865
Price to book
131.87
Price to tangible book (TTM)
367.75
Price to free cash flow (TTM)
-12.544
Free cash flow yield (TTM)
-7.97%
Free cash flow per share (TTM)
-0.062
Growth
Earnings per share change (TTM)
-37.04%
3-year revenue growth (CAGR)
-77.29%
3-year earnings per share growth (CAGR)
-12.36%
What the Analysts think about Avacta Group Plc
Analyst ratings (Buy, Hold, Sell) for Avacta Group Plc stock.
Analyst projections of the future price of Avacta Group Plc stock.
Bulls say / Bears say
AVA6000 generated encouraging early clinical signals in salivary-gland cancer, including four partial responses and nine minor responses among 38 evaluable patients, alongside a 92% disease-control rate and no severe cardiac-toxicity events in 111 treated patients. (Avacta)
The FDA agreed a potential pivotal-trial design for AVA6000 using a single study and progression-free survival as the sole primary endpoint, which could provide a clearer and potentially faster regulatory route if Phase 1b data mature positively. (Avacta)
AVA6103 has become Avacta’s second clinical program, with the first patient treated in the FOCUS-01 Phase 1 trial and enrollment underway at three U.S. oncology centers; initial clinical data are expected later in 2026. (Avacta)
Avacta remains a clinical-stage biotech with no approved commercial product; even after agreeing a potential pivotal AVA6000 trial design with the FDA, the company stated that further development depends on securing a partner. (Avacta)
Data summarised monthly by Lightyear AI. Last updated on 14 Sept 2026.
Avacta Group Plc Financial Performance
Revenues and expenses
Avacta Group Plc Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.